argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-16 07:31 |
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneo…
|
English | 98.7 KB | ||
| 2024-06-26 10:02 |
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neur…
|
English | 119.1 KB | ||
| 2024-06-24 07:33 |
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demye…
|
English | 72.3 KB | ||
| 2024-06-17 07:14 |
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patien…
|
English | 62.5 KB | ||
| 2024-06-04 07:38 |
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
English | 18.1 KB | ||
| 2024-05-09 16:20 |
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
|
English | 124.7 KB | ||
| 2024-05-08 08:35 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 25.1 KB | ||
| 2024-05-07 08:32 |
argenx to Present at BofA Securities 2024 Health Care Conference
|
English | 22.2 KB | ||
| 2024-05-02 07:44 |
argenx to Report First Quarter 2024 Financial Results and Business Update on Ma…
|
English | 25.2 KB | ||
| 2024-04-16 07:34 |
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transform…
|
English | 144.4 KB | ||
| 2024-03-27 08:29 |
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disea…
|
English | 42.1 KB | ||
| 2024-03-27 08:20 |
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
|
English | 24.6 KB | ||
| 2024-03-26 07:45 |
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults wi…
|
English | 60.5 KB | ||
| 2024-03-21 09:16 | English | 51.6 MB | |||
| 2024-03-08 07:42 |
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at…
|
English | 96.0 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
